Empagliflozin

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility? The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare. Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all. #SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

📉💊 Sustainable diabetes medication pricing could transform access for millions! A recent study reveals how competitive biosimilar manufacturing can slash yearly treatment costs to as low as $96. Find out how policy changes and market competition can lead to affordable care for all. 🌍💡 #DiabetesCare #AffordableMedication #HealthcarePolicy #Biosimilars #LifeSciencesConsulting #ValueBasedHealthcare 👉 Read our full article and join the conversation on how we can make diabetes treatments accessible

Uncover the potential of SGLT2 inhibitors in managing diabetes and associated conditions. 📚💡🔬Our latest article delves into their cost-effectiveness and future prospects. Read now to stay informed! #DiabetesTreatment #HealthcareInnovation #SGLT2Inhibitors 💊🔬

🌎💡 New insights into Chronic Kidney Disease (CKD)! 🚀 Our latest article, featuring a published interview with renowned nephrologist Sylvia Rosas, MD, explores why CKD often goes unnoticed and the implications of recent research on CKD screening, treatment strategies, and the economics of CKD management. 📚 #CKD #Healthcare #Research #KidneyDisease. Discover more here.

📊New study reveals the hidden economic burden of early-stage CKD in Japan 🇯🇵. Discover how proactive interventions can help reduce excess healthcare spending 💰. Read more ➡️ #CKD #HealthcareEconomics #Interventions #JapanHealthcare

First 10 Drugs Announced for Medicare Price Negotiation On August 29, 2023, the Biden-Harris administration revealed the first 10 drugs chosen for Medicare price negotiation under the Inflation Reduction Act (IRA). Five of these drugs treat cardiovascular conditions such as atrial fibrillation and heart failure. This is a significant step towards improving access to lifesaving therapies for cardiovascular conditions that affect millions of older US residents. The rising prevalence of cardiovascular and metabolic diseases in the elderly (65 years and […]

Introduction: The Pharmaceutical Benefits Scheme (PBS) included Empagliflozin, a sodium glucose co transporter 2 (SGLT2) inhibitor, for chronic heart failure (CHF) treatment with reduced ejection fraction (LVEF ≤40%) starting April 1, 2022. Yet, the Pharmaceutical Benefits Advisory Committee (PBAC) decided in November 2022 not to endorse Empagliflozin for treating CHF in patients with a left ventricular ejection fraction over 40%. They based their decision on the high unmet clinical need and the economic model’s failure to capture the disease’s progressive […]